BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.14−0.21 (-8.94%)
Close on Nov 13, 2026Market cap $171.57MP/E –Yield –
BridgeBio Oncology Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
BridgeBio Oncology Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $156.69M, up 52.6% year over year. For fiscal 2025 it was $121.20M, up 65.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.20M | +65.8% |
| FY2024 | Dec 31, 2024 | $73.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $29.59M | -15.6% |
| Q2 FY2026 | Jun 30, 2026 | $49.23M | +79.4% |
| Q1 FY2026 | Mar 31, 2026 | $39.80M | +92.9% |
| Q4 FY2025 | Dec 31, 2025 | $38.07M | +94.9% |
| Q3 FY2025 | Sep 30, 2025 | $35.05M | +95.9% |
| Q2 FY2025 | Jun 30, 2025 | $27.44M | – |
| Q1 FY2025 | Mar 31, 2025 | $20.64M | – |
| Q4 FY2024 | Dec 31, 2024 | $19.54M | – |
| Q3 FY2024 | Sep 30, 2024 | $17.89M | – |
See a number that looks wrong?